Skip to main content
HR 6417 116th Congress House

Protecting Cures Act of 2020

Official title: To prohibit the Secretary of Health and Human Services from withholding funds for certain research using human fetal tissue, and for other purposes.

Introduced: March 31, 2020 Introduced by: Schakowsky, Janice D. Democratic · Illinois See on congress.gov
Health Cell biology and embryologyMedical ethicsMedical researchOrgan and tissue donation and transplantationResearch administration and funding
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 31, 2020
Referred to the House Committee on Energy and Commerce.
Mar 31, 2020
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action March 31, 2020

Referred to the House Committee on Energy and Commerce.

 Plain-English summary Congressional Research Service

Protecting Cures Act of 2020

This bill prohibits the Department of Health and Human Services from withholding funding, because of ethical considerations, for research activities that use human fetal tissue, provided that the research activities have been recommended for approval by an institutional review board and otherwise comply with existing laws concerning human fetal tissue. The bill also establishes that this research is not unethical by deeming the 1988 report of the Human Fetal Tissue Transplantation Research Panel as meeting relevant statutory requirements with respect to approving the ethical status of such research.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 18
All 18 Democratic 16
D
McGovern, James P.
Massachusetts · Oct 30, 2020
 D
Raskin, Jamie
Maryland · Oct 23, 2020
 D
Chu, Judy
California · Oct 20, 2020
HASTINGS, ALCEE
· Oct 20, 2020
 D
Pressley, Ayanna
Massachusetts · Oct 20, 2020
 D
Welch, Peter
Vermont · Oct 20, 2020
 D
Cohen, Steve
Tennessee · Jun 26, 2020
 D
Hayes, Jahana
Connecticut · Apr 28, 2020
 D
Carson, André
Indiana · Apr 7, 2020
 D
Norton, Eleanor Holmes
District of Columbia · Apr 7, 2020
 D
DeGette, Diana
Colorado · Mar 31, 2020
 D
DelBene, Suzan K.
Washington · Mar 31, 2020
 D
Frankel, Lois
Florida · Mar 31, 2020
 D
Huffman, Jared
California · Mar 31, 2020
 D
Nadler, Jerrold
New York · Mar 31, 2020
 D
Pocan, Mark
Wisconsin · Mar 31, 2020
Speier, Jackie
· Mar 31, 2020
 D
Watson Coleman, Bonnie
New Jersey · Mar 31, 2020
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 6417: Protecting Cures Act of 2020. 116th Congress. Open America. https://openamerica.io/bill/116-HR-6417/
MLA
"H.R. 6417: Protecting Cures Act of 2020." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-6417/.
Bluebook (legal)
H.R. 6417, 116th Cong. (2026), https://openamerica.io/bill/116-HR-6417/.
Markdown link
[H.R. 6417: Protecting Cures Act of 2020](https://openamerica.io/bill/116-HR-6417/)
Report a problem